Multifunctional Nanoparticle Approach for Targeting Melanoma

Jun Li; Jun Xie; Jintao Zhu; Jun Tao

doi:10.1016/j.jisp.2018.09.011

Multifunctional Nanoparticle Approach for Targeting Melanoma

J Investig Dermatol Symp Proc. 2018 Dec;19(2):S89-S90. doi: 10.1016/j.jisp.2018.09.011.

Authors

Jun Li¹, Jun Xie², Jintao Zhu³, Jun Tao⁴

Affiliations

¹ Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Hubei Key Lab of Materials Chemistry and Service Failure, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, Wuhan, China.
³ Hubei Key Lab of Materials Chemistry and Service Failure, School of Chemistry and Chemical Engineering, Huazhong University of Science and Technology, Wuhan, China.
⁴ Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: tjhappy@126.com.

PMID: 30471762
DOI: 10.1016/j.jisp.2018.09.011

Abstract

Malignant melanoma is the most aggressive and lethal form of skin cancer with an increasing incidence worldwide. In the past 5 years, the Food and Drug Administration has approved six targeted therapies or immunotherapies for the treatment of metastatic melanoma (Chapman et al., 2011; Falchook et al., 2012; Hauschild et al., 2012; Hodi et al., 2010; Ribas et al., 2015; Topalian et al., 2014). For the first time, interventions improve survival of this deadly disease. However, rapid resistance to BRAF/MEK inhibitors and lower rates of objective response or immune-related side effects for anti-CTLA-4 or anti-PD-1 monoclonal antibodies limited their widespread clinical applications.